TORONTO--(BUSINESS WIRE)--Acerus Pharmaceuticals Corporation (TSX:ASP) announced today that Tom Rossi, President and Chief Executive Officer of Acerus, is scheduled to present an overview of the company at the sixth annual Bloom Burton & Co. Healthcare Investor Conference. Mr. Rossi’s address will take place at the Sheraton Centre Toronto Hotel on May 2, 2017 at 4:00 p.m. Eastern Time.
The 2017 Bloom Burton & Co. Healthcare Investor Conference brings together Canadian, U.S. and European investors interested in the latest developments in the Canadian healthcare sector. Attendees will have an opportunity to obtain corporate updates from approximately 60 premier Canadian publicly traded and private healthcare companies through presentations, panel discussions, and private one-on-one meetings.
About Acerus
Acerus Pharmaceuticals Corporation is a
fully-integrated, Canadian specialty pharmaceutical company engaged in
the development, manufacture, marketing and distribution of innovative,
branded products in Men’s and Women’s Health. Acerus’ shares trade on
TSX under the symbol ASP. For more information, visit www.aceruspharma.com
and follow us on Twitter
and LinkedIn.
Notice regarding forward-looking statements
Information in
this press release that is not current or historical factual information
may constitute forward-looking information within the meaning of
securities laws. Implicit in this information are assumptions regarding
our future operational results. These assumptions, although considered
reasonable by the company at the time of preparation, may prove to be
incorrect. Readers are cautioned that actual performance of the company
is subject to a number of risks and uncertainties, and could differ
materially from what is currently expected as set out above. For more
exhaustive information on these risks and uncertainties you should refer
to our annual information form dated March 7, 2017 that is available at www.sedar.com.
Forward-looking information contained in this press release is based on
our current estimates, expectations and projections, which we believe
are reasonable as of the current date. You should not place undue
importance on forward-looking information and should not rely upon this
information as of any other date. While we may elect to, we are under no
obligation and do not undertake to update this information at any
particular time, whether as a result of new information, future events
or otherwise, except as required by applicable securities law.
